The tumor microenvironment is increasingly recognized as a major factor influencing not only malignant development, but also resistance to anticancer therapies. It is now evident that the myeloid regulatory cell (MRC) network plays a major role in the failure of antitumor immune responses and therapies to eradicate tumors. Therefore, interventions that can control the effects of tumors on myeloid regulatory cell development are important innovative strategies that should improve the clinical efficacy of novel and conventional therapeutic modalities. Although a crucial role of the MRC in tumor-associated immune suppression has been established, the nature of specific MRC populations and the inter-differentiation pathways of MRC development in cancer remain uncertain. This significantly limits our understanding of the biology of tumor progression and the development of targeted therapeutics to control appearance and differentiation of MRC populations in cancer. Our major hypothesis is that the tumor microenvironment differentially controls emergence of specific myeloid regulatory cell populations which, however, can be redirected by molecular-targeted therapy to support recovery of the antitumor immunity and improve the efficacy of cancer immunotherapy. To test our hypothesis, Aim 1 will characterize myeloid regulatory cell differentiation in the tumor environment in vivo, Aim 2 will determine the mechanisms of myeloid regulatory cell differentiation in the tumor environment, and Aim 3 will define the clinical feasibility of targeting myeloid regulatory cell subsets in the animal tumor models. Successful completion of these studies will 1) provide new insights into the immunobiology of myeloid regulatory cell subsets, including suppressor/regulatory dendritic cells, in cancer by addressing a critical barrier to progress in the field of tumor-mediated immunomodulation, 2) expand an existing paradigm and clinical practice of using FDA-approved pharmacological agents in immunotherapeutic protocols, and 3) support clinical development of molecular targeting of myeloid regulators to maximize the therapeutic value of different therapeutic modalities. Overall impact. The probability that the results of this proposal will contribute considerable levels of new knowledge and exert a potent influence on advancing the field of tumor immunotherapy is quite high. This is due to the many innovative questions and approaches that will be evaluated. This increases the possibility that important information will be collected, and contribute to the pool of information necessary to establish differential targeting of MRC as a highly relevant and useful therapeutic approach that, at least for certain types of cancer, may improve successful outcomes following translation into human clinical trials.

Public Health Relevance

The major translational goal of this proposal is to provide the mechanistic insights into developing a highly effective neoadjuvant strategy that targets major regulatory cell subsets in the tumor microenvironment. Understanding the mechanisms of an efficient reversal of the immunosuppressive network in cancer milieu using certain chemotherapeutic agents in ultra low noncytotoxic dose acting as molecular-targeted therapy will open a new avenue for cancer treatment and significantly improve the efficacy of existing therapeutic modalities. Together with shown immunomodulating and therapeutic potential of molecular-targeted therapy in different tumor models, these studies will provide essential preclinical data and rationale for clinical testing of an inventive combinatorial immunological approach in patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA154369-02
Application #
8286881
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Muszynski, Karen
Project Start
2011-07-01
Project End
2016-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
2
Fiscal Year
2012
Total Cost
$312,439
Indirect Cost
$104,939
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Shurin, Michael R; Ma, Yang; Keskinov, Anton A et al. (2016) BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo. Cancer Res 76:4959-69
Keskinov, Anton A; Tapias, Victor; Watkins, Simon C et al. (2016) Impact of the Sensory Neurons on Melanoma Growth In Vivo. PLoS One 11:e0156095
Zong, Jinbao; Keskinov, Anton A; Shurin, Galina V et al. (2016) Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother 65:821-33
Zhao, Yong; Burkert, Seth C; Tang, Yifan et al. (2015) Nano-gold corking and enzymatic uncorking of carbon nanotube cups. J Am Chem Soc 137:675-84
Seo, Wanji; Kapralov, Alexandr A; Shurin, Galina V et al. (2015) Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications. Nanoscale 7:8689-94
Keskinov, Anton A; Shurin, Michael R (2015) Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology 220:236-42
Landreneau, Joshua P; Shurin, Michael R; Agassandian, Marianna V et al. (2015) Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenviron 8:57-64
Shvedova, Anna A; Kisin, Elena R; Yanamala, Naveena et al. (2015) MDSC and TGFβ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes. Cancer Res 75:1615-23
Shurin, Michael R; Umansky, Viktor; Malyguine, Anatoli et al. (2014) Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22-25 April 2013, Krakow, Poland. Cancer Immunol Immunother 63:73-80
Shurin, Michael R; Yanamala, Naveena; Kisin, Elena R et al. (2014) Graphene oxide attenuates Th2-type immune responses, but augments airway remodeling and hyperresponsiveness in a murine model of asthma. ACS Nano 8:5585-99

Showing the most recent 10 out of 25 publications